nus.edu.sg Objective To examine viral evolutionary changes and their relationship to hepatitis B e antigen (HBeAg) seroconversion. Design A matched case–control study of HBeAg seroconverters (n=8) and ...

The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, ...

In this study, we answered two major questions that relate to use of transgenic plants for oral hepatitis B vaccines. First, we showed that an antigen from a non-enteric human pathogen (HBV ...

The WHO recommends vaccination against 12 deadly diseases in childhood, but how long does protection last, and how do they ...

Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Normandie Univ, INSA Rouen, UNIROUEN, CNRS, COBRA (UMR 6014), 76000 Rouen, France ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor (XNCR) and Alnylam (ALNY). Read more here.

Previously, the company said the investigational combo reduced hepatitis B surface antigens—one of the study’s four primary endpoints. At the time, Vir said it would not be moving the asset ...

Objectives To reveal the prevalence and associated influencing factors of hepatitis B among a rural residential population in Zhejiang, China, in order to help develop specific control strategies.

These Phase 1b data, in 34 chronically infected hepatitis B patients, on nucleos(t ... declines in HBV surface antigen (HBsAg) ranging from -2.3 to -0.4 log10 IU/mL were observed in 7 patients ...

Not only is the hepatitis B virus responsible for 54% of liver cancer cases, but the Centers for Disease Control and Prevention (CDC) recommends that all adults aged 19-59 get vaccinated against ...

Hepatitis B is a liver infection that inflames the organ ... "They do so by exposing the body to an active ingredient called an antigen which triggers an immune response," Brull says.